Opendata, web and dolomites

Need2immune SIGNED

Personalized liposomal cancer vaccines within days by rapid formulation screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Need2immune project word cloud

Explore the words cloud of the Need2immune project. It provides you a very rough idea of what is the project "Need2immune" about.

complete    systemic    administration    oncology    cargo    sustained    agents    tumour    levels    host    onco    mechanism    central    therapy    drastically    microneedles    risk    molecules    ease    modulators    cells    serum    combination    adverse    mainstream    direct    delivering    nanoparticles    period    serious    shown    harbours    injections    cancer    painlessness    clinical    kill    checkpoint    play    classes    trackable    attracting    possibility    immunotherapeutic    toxicity    autoimmune    microneedle    action    anticipated    understand    locally    bloodstream    vaccine    administer    immunotherapy    use    accelerate    administered    patients    tools    mobilise    lower    immune    personalised    eradication    remissions    decrease    easily    unprecedented    strategies    injected    doses    transdermal    immunotherapies    drugs    drawbacks    localised    efficacy    reagents    causing    therapeutic    intradermal    losing    reactions    drug    inject    autoimmunity    last   

Project "Need2immune" data sheet

The following table provides information about the project.

Coordinator
TECODEVELOPMENT GMBH 

Organization address
address: MARIE-CURIE-STR. 1
city: RHEINBACH
postcode: 53359
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 162˙806 €
 EC max contribution 162˙806 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECODEVELOPMENT GMBH DE (RHEINBACH) coordinator 162˙806.00

Map

 Project objective

Cancer immunotherapy, defined as the ability to mobilise the host’s own immune system to kill cancer, has recently within the last 5 years, taken a central role within mainstream oncology. This period has seen the field rapidly accelerate towards unprecedented clinical responses in patients, and the development of novel classes of immunotherapeutic drugs. One approach has been to design more personalised immunotherapies along with new methods in delivering the therapeutic cargo. It is anticipated that this will play a defining role for cancer immunotherapy in terms of how to better achieve sustained remissions or complete eradication. One of the challenges in the future will be to understand how to administer these molecules since the current approach of systemic administration harbours the risk of causing serious toxicity and/or autoimmunity. This could drastically lower the serum levels of immune reagents needed with a decrease in adverse effects and lower risk of autoimmune reactions, without losing systemic efficacy. Currently, cancer immunotherapies are injected into the bloodstream but systemic injections have many drawbacks. It could be more effective therefore to inject this kind of therapy locally and directly to target tumour cells. This proposal will be to implement a more direct approach, where the immunotherapy's effects could be more easily controlled, with also the possibility for lower doses to be administered. Recently, microneedles have been attracting attention as new drug delivery tools. The microneedle has already been shown to be a highly effective intradermal and transdermal vaccine delivery method due to its mechanism of action, painlessness and ease of use. The goal is therefore to use microneedles to deliver localised doses of combination immunotherapies, e.g. vaccine with checkpoint modulators, in nanoparticles, as the focus of a novel approach to developing new strategies for the trackable delivery of onco-immunotherapeutic agents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEED2IMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEED2IMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More  

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

ICARUS (2020)

Information Content of locAlisation: fRom classical to qUantum Systems

Read More